AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity ...Middle East

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill....

Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity )

Also on site :

• Uno de los médicos acusados ​​de suministrar ketamina a Matthew Perry acepta declararse culpable, según muestra el documento
• This Common Over-the-Counter Medication May Harm Brain Health, Doctors Say—Do You Take It?
• In Q1 2025, enterprise SaaS M&A deal count hit 210, according to PitchBook